Autologous Transfusion – Pros and Cons from the Health Policy Perspective

Publisher： Karger

E-ISSN： 1660-3818|29|3|110-116

ISSN： 1660-3796

Source： Transfusion Medicine and Hemotherapy, Vol.29, Iss.3, 2002-07, pp. : 110-116

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Autologous blood transfusion plays a significant part in hemotherapy. This relates not only to the legal stipulations as established in the Transfusion Act and handed down through court decisions but is also true under therapeutic aspects where many meaningful approaches towards autologous procedures are being made. Over and beyond that, autologous blood is a contribution towards self-sufficiency in blood and blood products. It becomes obvious that the various procedures for autologous blood transfusion need to be subjected to a differentiated legal but especially technical analysis. Not all procedures are already fully accepted. Irrespective of the fact that even autologous methods carry risks, it is always necessary to take a critical look at the treatment strategies that involve autologous blood and to subject them to continuous evaluation. Here, too, quality assurance is central to ensure optimum patient care. The new EU Directive setting standards of quality and safety for human blood and blood components in the European Union also covers the production of autologous blood donations.